PE firm launches oncology management group, acquires Indiana oncology practice — 4 insights

Pharos Capital Group acquired Lafayette, Ind.-based Horizon Oncology and concurrently launched its own venture, Verdi Oncology.

Advertisement

Here’s what you should know.

1. Verdi is an oncology practice and clinical research management company. Wes Chapman, a Pharos Capital partner, will serve as the firm’s CEO.

2. The terms of the transaction were not disclosed.

3. Horizon has four oncology and hematology providers. The practice offers clinical trial opportunities to its patients.

4. Horizon Founder Wael Harb, MD, said he was “excited to partner with Pharos and Verdi.”

More articles on transactions/valuations:
7 things for ASC leaders to know for Thursday — March 22, 2018
10 things to know about Regent Surgical Health
How freight management uncovers hidden cost savings in ASC supply chain

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.